
Positioning CELMoDs Alongside CAR T-Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
In this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss how emerging evidence for CELMoDs may influence treatment selection at first relapse in multiple myeloma, particularly alongside CAR T-cell therapy and bispecific antibodies.
In this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss how emerging evidence for CELMoDs may influence treatment selection at first relapse in multiple myeloma, particularly alongside CAR T-cell therapy and bispecific antibodies. Dr. Richardson highlights the practical limitations of cellular and bispecific therapies, noting that patient frailty, age, preferences, and treatment-related infection risks may limit eligibility. He describes CELMoDs as an additional treatment pillar, emphasizing the promising MRD negativity and progression-free survival findings with iberdomide plus daratumumab and dexamethasone in the EXCALIBER-RRMM trial. The experts consider how these findings may influence the positioning of iberdomide relative to pomalidomide-based regimens, while acknowledging differences in the available evidence for overcoming pomalidomide refractoriness. Dr. Mikhael emphasizes that treatment selection should not rely on rigid hierarchies between therapeutic approaches. Instead, clinicians should assess risk, frailty, safety, efficacy, and practicality while incorporating patient preferences through shared decision-making. The discussion underscores the importance of preserving multiple treatment options and individualizing therapy according to each patient's circumstances.
Related to this article








